ArticleMicrosurgery2026
Magnesium-Doped Artificial Bone Combined With Pedicled Peri-Acetabular Bone Flap for ARCO Stage II Osteonecrosis of the Femoral Head: A Comparative Study.
Article in Microsurgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveMagnesium (Mg) ions promote bone regeneration. Combined with a vascularized periosteal flap providing blood supply and mechanical support, this approach may improve outcomes for osteonecrosis of the femoral head (ONFH), but its clinical efficacy is unclear. This study compared this approach with conventional core decompression (CD) for Association Research Circulation Osseous (ARCO) Stage II ONFH.
methodsA retrospective analysis was conducted on 76 patients (82 hips) with ARCO Stage II ONFH. The observation group (OG) (39 patients, 44 hips) received Mg-doped artificial bone combined with pedicled peri-acetabular bone flap (MAB-PPBF), while the control group (CG) (37 patients, 38 hips) underwent CD. Operative time, intraoperative blood loss, Harris Hip Score (HHS), Visual Analog Scale (VAS), ARCO stage, Kerboul angle, and hip-preserving success rate were compared.
resultsBaseline characteristics were comparable between groups. The OG had longer operative time (47.9 ± 7.2 vs. 44.2 ± 3.5 min) and greater blood loss (36.2 ± 8.1 vs. 27.3 ± 7.1 mL) than the CG (p < 0.05). At final follow-up, the OG showed significantly higher HHS (84.12 ± 3.14 vs. 81.94 ± 2.09) and lower VAS (2.97 ± 0.43 vs. 3.32 ± 0.76) compared with controls (p < 0.05). The OG also had a higher proportion of ARCO Stage II (47.6% vs. 30.0%) and lower proportion of Stage IV (4.8% vs. 16.7%, p < 0.05). The Kerboul angle was significantly smaller in the OG (203.54° ± 32.84° vs. 221.39° ± 31.82°, p < 0.05). The hip-preserving success rate was significantly higher in the OG (90.9%, 40/44) than in the CG (65.8%, 25/38, p < 0.05).
conclusionFor ARCO Stage II ONFH, MAB-PPBF achieves more thorough necrotic bone removal, adequate grafting, accelerated bone regeneration, effective hip pain relief, improved hip function, and delayed disease progression compared with CD, showing superior clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.